T
TEVA icon

Transce3nd’s Teva Pharmaceuticals TEVA Stock Holding History

Transce3nd’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-774
Closed -$13K – 1047
2025
Q2 		$13K Sell
774
-47
-6% -$758 0.01% 522
2025
Q1 		$12.6K Buy
821
+266
+48% +$4.75K 0.01% 524
2024
Q4 		$12.2K Buy
+555
New +$10.1K ﹤0.01% 686

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Transce3nd's TEVA Position: Q3 2025 in Review

Transce3nd sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 774 shares — an estimated $13K sold.

Transce3nd first reported a position in TEVA in Q4 2024 and held it in 3 quarters. The position peaked at $13K in Q2 2025. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Transce3nd reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Transce3nd sold 774 Teva Pharmaceuticals shares in Q3 2025, an estimated $13K.
  • Transce3nd first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Transce3nd's Teva Pharmaceuticals position peaked at $13K in Q2 2025.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Transce3nd's 13F filing for Q3 2025, filed 12 Nov 2025.